Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 10/20 | 0.49 |
| ▸ | TTK | P33981 | 4/20 | 0.49 |
| ▸ | CSF1R | P07333 | 2/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | PLK1 | P53350 | 8/20 | 0.48 |
| ▸ | PLK3 | Q9H4B4 | 4/20 | 0.48 |
| ▸ | PLK2 | Q9NYY3 | 4/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1785037 | 0.81 | CDK2 (0.56) | PRKDCTTKPTK2PLK1AURKA | |
| SCHEMBL4794798 | 0.79 | PLK1 (0.64) | PLK1PLK3PLK2 | |
| SCHEMBL3548112 | 0.78 | RAD52 (0.60) | TTKPLK1PLK3PLK2 | |
| SCHEMBL3549528 | 0.77 | PLK1 (0.66) | PLK1PLK3PLK2 | |
| SCHEMBL1560401 | 0.77 | PLK1 (0.76) | PLK1PLK3PLK2 | |
| SCHEMBL3540977 | 0.76 | PLK1 (0.65) | PLK1PLK3PLK2 | |
| SCHEMBL1781821 | 0.76 | TTK (0.59) | PRKDCTTKCSF1RPTK2PLK1 | |
| SCHEMBL23948470 | 0.76 | PRKDC (0.63) | PRKDCTTKCSF1RAURKAKCNH2 | |
| SCHEMBL3545697 | 0.76 | PLK1 (0.64) | PLK1PLK3PLK2 | |
| SCHEMBL1781601 | 0.75 | PRKDC (0.55) | PRKDCTTKCSF1RAURKACCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | PRKDC 163/4885TTK 4/4885CSF1R 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.